

Review of Challenges in Performing Real-World Evidence Studies for Nonprescription Products

Christian Maihöfner¹, Theresa Mallick-Searle², Jan Vollert³, Pranab Kalita⁴, Vidhu Sood Sethi⁵

¹Department of Neurology, General Fürth Hospital, University of Erlangen, Fürth, Germany; ²Division of Pain Medicine, Stanford Health Care Pain Management Clinic, Palo Alto, CA, USA; ³Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK; ⁴Global Category Medical Affairs, Haleon Plc, Weybridge, England, UK; ⁵Global Medical Affairs, GSK Consumer Healthcare Singapore Pte. Ltd, Singapore

Correspondence: Vidhu Sood Sethi, GSK Consumer Healthcare Singapore Pte Ltd (Co Regn No. 201309040M), 23 Rochester Park #03-02, 139234, Singapore, Tel +6596447203, Email vidhu.x.sethi@haleon.com

Abstract: In recent years, regulatory authorities have signaled a willingness to consider real-world evidence (RWE) data to support applications for new claims and indications for pharmaceuticals. Historically, RWE studies have been the domain of prescription drugs, driven by the fact that clinical data on patients are routinely captured in medical records, claims databases, registries, etc. However, RWE reports of nonprescription drugs and supplements are relatively sparse due to methodological gaps in this area. The objective of this narrative review is to identify which RWE methodologies have been used to study nonprescription products. A total of 49 articles were included based on literature searches. Label comprehension studies, used to support prescription-to-nonprescription switches, are useful in determining how nonprescription products will be used; however, they provide no actual clinical data. The most common RWE studies of nonprescription products were cross-sectional surveys, which investigated a broad range of indications and were conducted in an array of settings, including online, by phone, point-of-sale (pharmacy), outpatient clinics, and shopping malls. However, while this type of study is effective for identifying use patterns and attitudes in the general population, recall bias limits the ability to collect safety and effectiveness data. Studies of electronic medical records and claims databases are hampered by incomplete or absent capturing of data on nonprescription products. As a result, most RWE studies to date have provided limited useful information. Although case reports and expert opinion should not be discounted, in the absence of other information they provide few actual data. Novel approaches using smartphone apps and artificial intelligence may provide new opportunities to collect RWE for nonprescription products, but these areas of research are in their infancy. Overall, there is a need to develop standards for execution of RWE studies of nonprescription products in terms of endpoints, study design, and study quality.

Keywords: cross-sectional studies, dietary supplements, evidence-based practice, nonprescription drugs, research design

Introduction

Real-world evidence (RWE) studies are typically used to investigate efficacy and safety of prescription drugs in routine clinical practice settings; the term *real-world evidence* in relation to healthcare appeared in the published literature at least as early as 1998.^{1,2} These studies help to expand the examined population from that limited by clinical trial inclusion/exclusion criteria to a wide range of participants, allowing confirmation of safety and efficacy in the broader population.^{1,3} RWE studies may also allow inclusion of distinct patient groups not included in clinical trials to be investigated. In addition, drugs can be studied over longer periods of time than are feasible with a randomized controlled trial (RCT). Perhaps more importantly, drug efficacy and safety can be assessed in a less supervised context than that seen in a clinical trial.

Variations in definitions of RWE frequently cause confusion in the interpretation and use of the real-world data used to generate RWE, especially in the regulatory setting. For the purposes of this review, we have followed the US Food and Drug Administration (FDA) definition of RWE as data collected during a noninterventonal study of a marketed drug administered during routine medical practice according to a healthcare provider's (HCP's) clinical judgment.⁴ These

studies can provide a range of important data and insights, including analysis of use patterns of marketed drugs as well as questionnaires, laboratory tests, or imaging studies. They can also be used to study off-label usage and to provide support or hypothesis generation for expanded indications and additional claims,⁵ as well as to determine important information about the clinical effects of drugs for rare diseases.

Typical RWE study designs include prospective and retrospective examination of registries, electronic medical records (EMR), and pharmacy and claims databases, as well as cross-sectional surveys.^{1,4,6} EMR and claims databases, however, all require HCPs to actively follow patients or, at a minimum, to input relevant health data into the database. To help navigate development of RWE study data, regulatory agencies, including FDA, European Medicines Agency (EMA), Health Canada, the UK National Institute for Health and Care Excellence (NICE), Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and regulatory agencies in China have developed guidance for use of RWE studies to support regulatory applications.^{4,7–11}

Although Phase IV postapproval commitment studies, spontaneous reports registries (eg, V-safe), and other safety studies required by regulatory agencies report data collected in a real-world setting, they are not the focus of this review.^{12,13} Interventional studies involving the use of drugs are usually defined as clinical investigations requiring a new drug application, so they do not represent RWE studies. However, observational real-world data may be of value for identifying potential participants for an interventional trial, to identify clinical endpoints (ie, hypothesis generating), or even as an external historical control for a single-arm study.

While most RWE focuses on prescription products and nonpharmacological interventions, study of nonprescription products (ie, medications and supplements) in this setting is of particular importance. Globally, with the greater awareness, emphasis, and adaption of self-care among the general population, as well as the associated switch of a number of products from prescription to nonprescription,¹⁴ there is an increasing need to generate RWE to understand how these products are experienced in a self-care setting. Recent guidance from the FDA¹⁵ and Medicines and Healthcare products Regulatory Agency¹⁶ has expanded RWE definitions to allow for RCTs when executed in real-world settings.

Collection of RWE for nonprescription products presents significant challenges. By definition, use of nonprescription products usually does not require involvement of HCPs, which can result in difficulties with patient recruitment, accurate data collection, and follow-up. As a result, methodological gaps exist in the research of nonprescription products in a real-world setting. The objectives of this narrative review are to identify RWE studies implemented for nonprescription products around the world and to explore the methodologies used to address some of these challenges, with a view to informing design of studies in this emerging area.

Materials and Methods

Literature searches in PubMed were conducted using the following terms: *dietary supplement(s)*, *nonprescription* or *over the counter*, and *real world* or *pharmacy* to identify relevant studies. A second search was conducted using Google Scholar with terms *over-the-counter* or *nonprescription*, and *real world* or *pharmacy*. Additional articles were identified during full-text review. Included articles described studies of nonprescription drugs conducted in a community setting outside the context of a formal clinical study. For this investigation, only RWE studies that reported on analysis of patient effectiveness and/or safety data of nonprescription drugs were included.

Results

The initial PubMed and Google Scholar searches yielded a total of 1744 articles that were screened (Figure 1).¹⁷ After review of titles and abstracts, most of these were eliminated because they did not describe actual studies or analysis of patient data; were limited to assessment of a disease state rather than investigation of the effectiveness and/or safety of a drug or supplement; or focused on symptom patterns before treatment or attitudes toward disease and treatment. Finally, a total of 49 articles described different methods of generating RWE data in the nonprescription setting and were included in the qualitative synthesis. These methods included RCTs (n=1), prescription-to-nonprescription switches (n=3), cross-sectional surveys (n=27), database studies (n=12), case reports (n=1), and novel approaches (n=5).




Figure 1 PRISMA flow diagram.¹⁷

Abbreviations: PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RWE, real-world evidence.

Randomized Controlled Trials

One RCT of a nonprescription cough remedy using RWE data was identified.¹⁸ Patients enrolled in the study were adults aged 18 years and older who self-referred to a general practitioner or pharmacist owing to a cough of less than 7 days' duration. The study had numerous inclusion and exclusion criteria. Briefly, patients with cough severity of at least 60 on a 100-mm visual analog scale were included, and patients with chronic cough and who smoked or used angiotensin-converting enzyme inhibitors were excluded. The primary endpoint was change in cough severity as recorded in a daily diary at 4 days of follow-up. This controlled study of a nonprescription product highlights one of the most effective ways of recruiting participants to such a study, ie, by a primary care physician or pharmacist.

Other reports, such as one examining the effects of a preparation containing two marine algae for treatment of metabolic syndrome, describe retrospective longitudinal studies.¹⁹ While such studies maintain many of the limitations of RCTs, in that inclusion/exclusion criteria limit the enrolled population (eg, by age, history of certain symptoms, use of specific prescription medications, and concomitant disease), they do not deliver the same quality of data as a formal trial because of their retrospective nature and lack of detailed follow-up. A number of other studies, both single-arm and comparative, that described themselves as RWE studies were excluded from the current review for these reasons.²⁰

Pragmatic trials are a variation of RCTs that incorporate elements of RWE data collection.²¹ These interventional studies retain many features of RCTs, while allowing for a broader patient population, and permit study of clinically meaningful outcomes beyond the narrow endpoints of RCTs. None were identified in our review.

Prescription-to-Nonprescription Switch

Label comprehension and actual use studies are critical steps in the switching of a pharmaceutical product from prescription to nonprescription. These studies help demonstrate that patients can appropriately self-identify that a particular drug is correct for their condition, and that they can safely follow directions for use without clinician oversight.²² Benefits of these studies include helping to identify the typical demographics of the patient population likely to take a nonprescription product and describing actual use patterns. One study showed that individuals (n=1999)

approached in a shopping mall could determine with 90% accuracy that omeprazole for management of frequent heartburn was an appropriate treatment for them.²³ The study further demonstrated that subjects were able to follow directions with 79% accuracy. In a similar study, 249 participants with a history of nonprescription analgesic use of 5 or more doses per month for the previous 3 months were recruited via newspaper advertisements, on-site advertising at the pharmacy, online advertising, or direct mail.²⁴ After a telephone screening, participants were randomized to a self-selection study or a compliance study of ibuprofen immediate release (IR)/extended release (ER) 600-mg caplets. Overall, 69.1% correctly self-selected the ibuprofen IR/ER formulation, and 5 participants (1.2%) used the drug for more than 10 consecutive days, indicating a low degree of inappropriate use. No differences in usage were noted in select demographic comparisons. However, in terms of RWE, a key limitation of these studies is that, by design, they collect few if any data on the safety and effectiveness of the product being studied.

A recent extension of this type of study utilized outcomes modeling data based on the typical patient.²⁵ The benefit of a nonprescription progestin-only contraceptive was modeled based on an actual-use study of women who chose to buy the drug, including data on the method of contraception used before study enrollment. Effectiveness was determined by calculating the expected number of pregnancies in two hypothetical cohorts of 100,000 women using different contraceptive methods over 1 year, basing expected failure rates on published outcomes. The analysis determined that as many as 30,624 unintended pregnancies could be prevented through use of the nonprescription progestin-only contraceptive.

Cross-Sectional Surveys

The most common RWE studies of nonprescription products found in our literature search were cross-sectional surveys, which are observational studies that collect and analyze data at a single time point.²⁶ These surveys have been conducted in numerous settings including online, by phone, point-of-sale (pharmacy), outpatient clinics, and shopping malls. The studies cover a range of therapeutic areas including headache and osteoarthritis pain, smoking cessation, allergy/asthma, common cold, dermatology, gastrointestinal symptoms, and vulvovaginal candidiasis. Table 1 summarizes the cross-sectional surveys of nonprescription products identified in our review.^{27–53}

Table 1 Summary of Real-World Cross-Sectional Surveys

Authors	Treatment	Number of Participants	Indication	Setting	Study Design	Endpoints
Storr et al ²⁷	HBB vs HBB + paracetamol vs peppermint oil	1686	Abdominal cramps	Pharmacy (community and online)	Patient survey among product users	Symptom severity, treatment efficacy
Bédard et al ²⁸	4 intranasal corticosteroids and 8 oral antihistamines	9122	Allergic rhinitis	Smartphone app (Allergy Diary)	Mobile phone survey	Allergic rhinitis symptoms and non-Rx medication use
Azzi et al ²⁹	Short-acting beta agonist	412	Asthma	Pharmacy	Cross-sectional observational study of product purchasers	Reliever use, asthma control, healthcare utilization
Swanepoel et al ³⁰	Hearing aids	656	Deafness	Online	Cross-sectional survey among users	Self-reported benefit and satisfaction
Ah et al ³¹	Non-Rx vs Rx topical corticosteroids	1103	Dermatology	Pharmacy or dermatology clinic	On-site survey and prospective follow-up among topical corticosteroid users	Use patterns; safety, predisposing factors related to adverse drug events
Libby et al ³²	Non-Rx/herbal treatments for diabetes	286	Diabetes	Primary care practice	Prospective survey of patients with diabetes mellitus	Hypoglycemic events, non-Rx/herbal supplement use
Alemanni et al ³³	Geffer effervescent granules	409	Digestive symptoms	Online	Retrospective observational quantitative interview	Symptom relief, quality of life, use patterns, consumer benefits, satisfaction
Eder et al ³⁴	Drotaverine	650	NA	Pharmacy	Observational, retrospective survey of product purchasers	Reason for use, treatment satisfaction, efficacy

(Continued)

Table 1 (Continued).

Authors	Treatment	Number of Participants	Indication	Setting	Study Design	Endpoints
Goldman et al ³⁵	Simethicone	4003	Infant colic	Online	Retrospective noninterventional questionnaire of parents recruited via social media	Efficacy
Maihöfner et al ³⁶	Diclofenac gel	467	Musculoskeletal pain	Pharmacy or online pharmacy	Prospective survey of product purchasers	Pain severity, functional impairment, treatment satisfaction
Hasford et al ³⁷	Diclofenac	446	Pain	Pharmacy	Prospective, noninterventional survey of product purchasers	Safety and efficacy, use patterns
Zhang et al ³⁸	Canesten (clotrimazole or fluconazole formulations)	475	Vulvovaginal candidiasis	Online	Retrospective observational quantitative interview of product users	Use patterns, symptom relief, quality of life
Giua et al ³⁹	<i>Alkalihalobacillus clausii</i> (formerly <i>Bacillus clausii</i>) probiotic	267	Digestive symptoms	Pharmacy	Pharmacist interview of purchasing customers followed by web-based questionnaire	Use patterns, symptom improvement, quality of life
Gaul et al ⁴⁰	Ibuprofen + caffeine	1124	Pain	Pharmacy	Survey of product purchasers	Efficacy, tolerability
Klimek et al ⁴¹	Ibuprofen + pseudoephedrine	1770	Common cold	Pharmacy	Anonymous written survey of product purchasers	Use patterns, symptom relief, quality of life
Phillipson et al ⁴²	Wick MediNait and/or Wick DayMed	457	Common cold	Online after in-pharmacy recruitment	Prospective, multisite observational study	Treatment satisfaction, symptom relief, adverse events
Gaul et al ⁴³	Aspirin + paracetamol + caffeine		Headache or any other pain	Pharmacy	Prospective survey of product purchasers	Reasons for purchase, use patterns, pain relief, tolerability
Hinkel et al ⁴⁴	Sodium picosulfate	1845	Constipation	Pharmacy	At-home survey of prior users purchasing product	Use pattern, effectiveness, adverse events
Schulz et al ⁴⁵	Ambroxol cough syrup	2707	Cough	Pharmacy	Prospective survey of consumers purchasing product	Use pattern, effectiveness, tolerability
Jolicoeur et al ⁴⁶	Nicotine patch and smoking cessation brochures	223	Smoking cessation	Shopping mall	In person survey with follow-up home calls	Quitting smoking
Kotz et al ⁴⁷	Smoking cessation aids	10335	Smoking cessation	Computer-assisted face-to-face interviews	Survey of participants who attempted smoking cessation recruited from the Smoking Toolkit Study	Use of smoking cessation aids, successful smoking cessation
Brown et al ⁴⁸	E-cigarettes	6134	Smoking cessation	Face-to-face computer-assisted interviews	Survey of participants who attempted smoking cessation recruited from the Smoking Toolkit Study	Use of smoking cessation aids, successful smoking cessation
Kotz et al ⁴⁹	Smoking cessation aids	1560	Smoking cessation	Face-to-face computer-assisted interviews	Survey of participants who attempted smoking cessation recruited from the Smoking Toolkit Study	Use of smoking cessation aids, successful smoking cessation
Jackson et al ⁵⁰	Smoking cessation aids	18,929	Smoking cessation	Computer-assisted telephone interviews	Survey of participants who attempted smoking cessation recruited from the Smoking Toolkit Study	Use of smoking cessation aids, successful smoking cessation
Jackson et al ⁵¹	Smoking cessation aids	1104	Smoking cessation	Computer-assisted telephone interviews	Survey of smokers who attempted smoking cessation recruited from the Smoking Toolkit Study	Use of smoking cessation aids, successful smoking cessation
Jackson et al ⁵²	Smoking cessation aids	7300	Smoking cessation	Computer-assisted or face-to-face or telephone interviews	Survey of participants who attempted smoking cessation recruited from the Smoking Toolkit Study	Use of smoking cessation aids, successful smoking cessation
Borland et al ⁵³	Smoking cessation aids	1101	Smoking cessation	Computer-assisted telephone interviews	Survey of participants who failed smoking cessation	Use of smoking cessation aids

Abbreviations: HBB, hyoscine butylbromide; NA, not applicable; Rx, prescription.

The sample sizes of the identified studies ranged from approximately 200 to 19,000 participants. It is beyond the scope of this review to determine the appropriateness of the sample size in each of these studies given the range of endpoints measured. However, as with any study, statistical power is predicated on the sensitivity of the endpoints in the studied population. Sample-size calculations should be based on the sensitivity and specificity of the endpoints and the anticipated drop-out rate, as with an RCT.

Most of the studies summarized in Table 1 report on drug/supplement usage patterns. Indeed, some studies, notably the smoking cessation studies, were designed to determine what products were being used by consumers to address their condition, while others were designed to assess how specific agents were being used, primarily to ensure proper use. Many of the studies, however, also reported on effectiveness (usually as some measure of symptom relief), patient-reported outcomes (including quality of life [QOL] and treatment satisfaction), and safety and tolerability. Prospective cross-sectional surveys, therefore, can provide data on how nonprescription products are being used and how consumers perceive their effectiveness in a real-world setting.

One study that reported the output from in-depth, semistructured telephone interviews with just 21 patients in the setting of smoking cessation was excluded from this review.⁵⁴ The data collected in this study were qualitative in nature and therefore did not meet our criteria for quantitative evidence that could be applied in a regulatory setting.

Database Studies

One of the most common forms of RWE studies for prescription products is database research.⁶ This approach can also be used for study of nonprescription products. However, the value of such databases depends on the quality and completeness of data collected, eg, whether complete information on nonprescription products or routine pain assessments was collected and entered into the database.⁵⁵ While some database studies are based on retrospective analysis of EMR, claims databases, and pharmacy databases, others are based on prospective, longitudinal, observational studies in which detailed information on a particular condition is collected. An example of a retrospective analysis of patient records is a study of metamizole in Brazil, where the drug is available on a nonprescription basis, to determine how it is used.⁵⁶ A total of 455,834 patients were recorded as having taken metamizole during the study period. The study found that the most common reason for use was pain (81%), followed by fever (19%); headache (19%), sore throat (8%), muscular pain (7%), and abdominal pain (5%). In another retrospective study of patient records, the effect of various nutraceuticals was studied in patients with dyslipidemia who were following a Mediterranean diet. In this study of 487 patients, the nutraceuticals were found to enhance the improvement of lipid profiles, although most patients did not achieve low-density lipoprotein-cholesterol goal.⁵⁷

A benefit of EMR analysis is the ability to query a very large population. An example of this is an analysis of 60,212 unique patients who had taken either ibuprofen 200 mg, naproxen 220 mg, or a combination of the two.⁵⁸ This study used International Classification of Diseases, Ninth Revision (ICD-9) codes to identify the proportion of these patients who experienced gastrointestinal complications. When the rate of complications on a nonsteroidal anti-inflammatory drug (NSAID) was compared with the time period 365 days before taking the drug, the odds ratio for gastrointestinal complications with naproxen was 1.54 (95% confidence interval [CI], 1.04–2.28; $p=0.03$) and with ibuprofen was 1.38 (95% CI, 1.07–1.78; $p=0.01$).

Pharmacy transaction data can also be used to generate RWE for nonprescription drugs. Three reports from Australia used the NostraData database, which provides a demographically representative dataset, to study allergic rhinitis.^{59–61} The first of these studies was limited to examining the seasonality of oral antihistamine and intranasal corticosteroid purchases.⁶⁰ A second study was able to determine the extent of multitherapy use compared with recommended intranasal corticosteroids alone.⁵⁹ The final study showed that many patients are purchasing nonprescription oral antihistamines that are not clinically effective.⁶¹ The study further showed that patients with prescriptions for comorbid respiratory conditions were more likely to purchase intranasal corticosteroids.

A common approach to analysis of medical databases is propensity score matching, in which patients in the database taking a particular drug or supplement are matched with otherwise similar patients not receiving the intervention, giving the ability to control for confounding participant characteristics without reducing the power of the model by scoring multiple confounders into one variable.⁶² A number of such analyses have been conducted with nonprescription

supplements. Two of these involved patients who did or did not take vitamin D. In one analysis, 10,974 patients hospitalized with heart failure and a history of vitamin D supplementation had a significantly lower risk of in-hospital mortality and mortality within 7 and 30 days of hospitalization than those who had not taken vitamin D.⁶³ In a separate analysis of a prospective, multicenter, longitudinal, observational cohort, 236 propensity score-matched patients with knee osteoarthritis who took vitamin D had no significant changes in pain or physical function during 2 years of follow-up compared with controls, consistent with RCTs.⁶⁴ A broader non-propensity-matched study conducted in the UK measured overall mortality among vitamin D and multivitamin users and nonusers.⁶⁵ Propensity score matching has also been used to study calcium supplementation in a Korean health claims database.⁶⁶ This approach has also been used to explore gender differences in smoking cessation effectiveness among users of varenicline or nicotine patches.⁶⁷

Case Reports

In some situations, no information on the role of certain products is available for specific populations. Case series reports can provide a limited amount of data and can be hypothesis generating. One such case series investigated the efficacy of a nonprescription dietary supplement of quebracho, conker tree, and *Mentha balsamea* Willd extracts over a 2-week period for treatment of irritable bowel syndrome in 24 patients.⁶⁸ Retrospectively compiled data found that symptoms of abdominal pain, constipation, and bloating improved in 88% of patients.

Novel Approaches

The use of smartphone apps to gather cross-sectional data has offered a new method for collection of RWE data. The Mobile Airways Sentinel Network (MASK) employed the mobile phone app Allergy Diary to collect information on allergic rhinitis symptoms in 9122 participants using 4 different intranasal corticosteroids and 8 oral antihistamines.²⁸ Data from 112,054 days were recorded. Although use of an app allows for ongoing follow-up that is not achievable with in-person telephone or online surveys, users were erratic in reporting symptom and treatment data. The study found that patients manage allergic rhinitis contrary to physician guidelines, increasing the number of treatments to control worsening symptoms, rather than adjusting dosage to achieve control. Data collected using the app showed that levocetirizine was the most effective oral antihistamine, and the study was able to differentiate between fluticasone furoate, mometasone furoate, and mometasone furoate plus azelastine. While this study demonstrates some of the weaknesses of online data collection, in that users did not enter data consistently and reliably, the volume of data collected allowed conclusions to be drawn; a pilot study of only 2871 users that preceded the above described study was likely too small to generate definitive conclusions, highlighting the need for a large sample size.^{28,69} A strength of this approach, however, is that it may help to reduce recall bias associated with cross-sectional surveys since data are inputted by the subject in real time. This points toward models for future real-world cross-sectional surveys of nonprescription products, meeting consumers where they are in the modern world. In addition, the ability to collect a wide array of data with this approach may allow for study of novel concepts. While the introduction of such new technologies may present some regulatory hurdles, the challenges associated with smartphone apps, such as patient confidentiality and data security, are not different from more established survey techniques.

One study highlighted the possibilities of using Google Trends to model allergic rhinitis symptoms and use of oral antihistamines. While this preliminary publication is limited to demonstrating the seasonality of disease symptoms and associated drug uptake, it shows a possible novel approach to mine the vast quantity of data collected by Google.⁷⁰ The use of social media presents a similar opportunity for health monitoring and signal detection by mining online content, owing to the vast quantity of data collected.⁷¹ Although so far limited to prescription drugs, social media can be used to monitor not only for adverse events, but also for off-label drug use and drug-drug interactions. The artificial intelligence (AI) revolution has led to the development of natural language processing (NLP). NLP allows words and phrases to be mined and has the potential to identify information about specific drugs, diseases, and adverse effects. However, a limitation of social media is the inability to verify cause-effect relationships between a drug and a specific adverse event reported by an individual patient.⁷¹

An area where NLP has already been applied is in the analysis of EMR data.⁷² While structured EMR data have proven useful, until now, analysis of unstructured clinical notes, which often contain information about supplement and

nonprescription drug use, has not been possible. A recent report conducted detailed surveys among 377 patients and compared the results with clinical notes using an NLP model. The NLP model achieved an F1 score (a measure of predictive performance) of 0.914, indicating a good performance of the model, although results varied for individual dietary supplements. The ability to conduct NLP analysis on EMR records may allow for more detailed research on the use of supplements and their potential effects.

Discussion

While RCTs may be the gold standard for generating robust clinical data with limited potential bias, RWE studies can provide information that informs day-to-day clinical practice in a less controlled environment that is closer to reality.³ This may especially be the case for nonprescription products that are taken without medical supervision and therefore may be taken under conditions different from those in which the product was originally studied and approved. RWE studies can help improve our understanding of effectiveness, safety, and usage patterns in populations larger and more diverse than can be studied in RCTs.^{1,3} In addition, they can help provide an early assessment of effectiveness and tolerability, as well as generating long-term data. These studies can also provide a view of unmet needs by identifying future needs and data gaps. A weakness of RCTs is that the inclusion/exclusion criteria make for a homogeneous study population that does not represent all possible users. RWE data can circumvent this weakness by allowing a wider array of participants and a larger sample size, owing to possible variability in effectiveness across different groups.

One argument against using RWE database and registry studies to inform clinical practice is that they do not provide the same robustness of data as RCTs, especially in the nonprescription setting.^{3,73} However, an appropriate study hypothesis supported by a protocol and statistical analysis plan that adjusts for the differences in population and data collection methods can account for these disparities in data integrity, accuracy, and quality. Another challenge of RWE data is the fact that EMR and claims databases are frequently incomplete when it comes to nonprescription drug use.⁷⁴ Although there is an awareness among experts regarding this deficiency, there is a need to educate HCPs on the importance of maintaining complete records. Statistical approaches toward handling any missing data in this context are required. It is recommended that propensity score matching be implemented in database studies to help reduce any confounding factors.

Cross-sectional surveys are the most common RWE studies of nonprescription products. These studies are not comparable to database and registry studies, which are based on clinical data. Indeed, participants surveyed outside of a medical setting do not represent a clinical population. As a result, these studies are limited by recall bias, ie, the accuracy and/or honesty of responses to survey questions by respondents, as well as potentially biased answers in response to leading questions, and social desirability bias.^{26,55} Survey questions should therefore be designed to minimize possible misunderstanding or inaccurate responses, as well as to probe aspects of the disease and its treatment that are important to the patient, including health-related QOL. Implementation of validated patient-reported outcome instruments would be one way to achieve this.

AI approaches, including NLP, that mine existing data to develop hypotheses have an advantage over RCTs in that they, by definition, query in a retrospective fashion. RCTs by contrast require that all endpoints are prespecified before any patient receives a drug. All such research, whether mining social media or EMR, requires that individual patient identities remain anonymous in accordance with standard ethics laws and practices. More research is required to determine the full potential and limitations of AI in this setting. A limitation of this review is that because the term *real-world* is often ill defined and frequently not used in potentially relevant studies, the results of the literature search may not be all-inclusive.²⁰ As a result, additional methodologies for RWE study of nonprescription products may not have been identified.

Although this review did identify a number of RWE studies for nonprescription products, the question of who will conduct future RWE studies remains. Since nonprescription drugs and supplements are usually taken without the advice of an HCP, the people who are typically the drivers of medical research are not best placed to conduct the research. Furthermore, HCPs cite time constraints as a barrier to collection of complete patient medical histories for input to EMR and other databases.⁷⁵ This means that many real-world studies of nonprescription products are destined to be funded and carried out by companies that market the product, raising questions about conflicts of interest. To mitigate this potential

bias, there is a need to create standards of RWE in terms of acceptable clinical endpoints and guidance for development of clinically robust patient-reported outcome surveys, as well as metrics for determining study quality. Implementation of these standards may allow for implementation of meta-analyses, which could further improve the credibility of RWE studies.

FDA, EMA, Health Canada, and Japan PMDA have all shown willingness to consider RWE data for inclusion in new drug approval applications or for line extensions of prescription drugs.⁵ Paying close attention to regulatory guidance for future design of RWE studies and patient recruitment may help improve study of nonprescription products and allow results to have a greater impact, especially in terms of driving expanded labels.^{4,7–11} However, this guidance is still evolving and primarily directed at development of prescription drugs. There are few examples of nonprescription products gaining new or expanded indications using real-world data; some examples include Vicks cold medicine, Sudocrem cream, Bepanthen ointment, and flurbiprofen lozenges. It is important for real-world data to be of good quality and known provenance (eg, patient-level data) so they can be evaluated.^{4,9}

One of the key recommendations from EMA to expand the data available for different outcomes and exposure across regions is to improve the number, size, and type of data sources.⁷ These include EMRs from secondary care settings, biobanks, large claims databases, and disease or patient registries. EMA also recommended developing collaborations between regulatory agencies and external stakeholders. With respect to nonprescription products, a limitation of these sources is that data on these products are not universally included and/or accurately recorded. Mechanisms for facilitating and incentivizing collection of data on nonprescription products are required to fulfill the EMA recommendation.

Conclusion

The recognition of RWE studies by regulatory bodies as being important sources of data on the effectiveness and safety of drugs has led to increased interest in this type of data generation. Development of more complete databases that capture nonprescription drug and supplement use would facilitate real-world study of these products. Proper design of study protocols, whether the study is prospective or retrospective, will help to improve the quality and utility of data. Newer approaches, including use of smartphone apps, and AI, including NLP, may help to facilitate RWE studies of nonprescription products.

Acknowledgments

Medical writing assistance was provided to the authors by James Street, PhD, Peloton Advantage, an OPEN Health company, and funded by Haleon (formerly GSK Consumer Healthcare).

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, acquisition and interpretation of data, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

Funding for this study was provided by Haleon (formerly GSK Consumer Healthcare).

Disclosure

VSS is an employee of Haleon. CM received honoraria for giving lectures for Haleon and was a member of advisory boards for Haleon. TM-S: Speakers' Bureau for Averitas Pharmaceuticals and AbbVie Pharmaceuticals. JV conducts contract research for Viartis and AstraZeneca. PK is an employee of Haleon. The authors report no other conflicts of interest in this work.

References

- Wieseler B, Neyt M, Kaiser T, Hulstaert F, Windeler J. Replacing RCTs with real world data for regulatory decision making: a self-fulfilling prophecy? *BMJ*. 2023;380:e073100. doi:10.1136/bmj-2022-073100
- Caro JJ, Speckman JL. Existing treatment strategies: does noncompliance make a difference? *J Hypertens Suppl*. 1998;16(7):S31–34.
- Eichler HG, Pignatti F, Schwarzer-Daum B, et al. Randomized controlled trials versus real world evidence: neither magic nor myth. *Clin Pharmacol Ther*. 2021;109(5):1212–1218. doi:10.1002/cpt.2083
- Guidance for industry considerations for the use of real-world data and real-world evidence to support regulatory decision-making for drug and biological products. 2023. Available from: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug>. Accessed February 9, 2024.
- Bolislis WR, Fay M, Kühler TC. Use of real-world data for new drug applications and line extensions. *Clin Ther*. 2020;42(5):926–938. doi:10.1016/j.clinthera.2020.03.006
- Dang A. Real-World Evidence: a Primer. *Pharmaceut Med*. 2023;37(1):25–36. doi:10.1007/s40290-022-00456-6
- Real-world evidence framework to support EU regulatory decision-making. 2023. Available from: https://www.ema.europa.eu/en/documents/report/real-world-evidence-framework-support-eu-regulatory-decision-making-report-experience-gained-regulator-led-studies-september-2021-february-2023_en.pdf. Accessed February 9, 2024.
- Guidance for Reporting Real-World Evidence. 2023. Available from: <https://www.cadth.ca/guidance-reporting-real-world-evidence>. Accessed February 9, 2024.
- NICE real-world evidence framework. 2022. Available from: <https://www.nice.org.uk/corporate/ecd9/chapter/overview>. Accessed February 9, 2024.
- Nishioka K, Makimura T, Ishiguro A, Nonaka T, Yamaguchi M, Uyama Y. Evolving acceptance and use of RWE for regulatory decision making on the benefit/risk assessment of a drug in Japan. *Clin Pharmacol Ther*. 2022;111(1):35–43. doi:10.1002/cpt.2410
- Li P, Wang S, Chen Y. Use of real-world evidence for drug regulatory decisions in China: current status and future directions. *Ther Innov Regul Sci*. 2023;57(6):1167–1179. doi:10.1007/s43441-023-00555-9
- Moneer O, Brown BL, Avorn J, et al. new drug postmarketing requirements and commitments in the us: a systematic review of the evidence. *Drug Saf*. 2022;45(4):305–318. doi:10.1007/s40264-022-01152-9
- Yates M, Bechman K, Galloway J. The use of real-world data to address questions of patient safety. *Rheumatology*. 2020;59(1):26–30. doi:10.1093/rheumatology/kez158
- Fisher M, Rawal K. A detailed analysis of the past 20 years of US FDA-approved prescription to over-the-counter switches. *Ther Innov Regul Sci*. 2023;57(5):1074–1080. doi:10.1007/s43441-023-00547-9
- Submitting documents using real-world data and real-world evidence to FDA for drug and biological products. *Guidance for Industry*. 2022. Available from: <https://www.fda.gov/media/124795/download>. Accessed October 7, 2024.
- MHRA guideline on randomised controlled trials using real-world data to support regulatory decisions. 2021. Available from: <https://www.gov.uk/government/publications/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions/mhra-guideline-on-randomised-controlled-trials-using-real-world-data-to-support-regulatory-decisions>. Accessed October 10, 2024.
- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. doi:10.1136/bmj.n71
- Birring SS, Brew J, Kilbourn A, Edwards V, Wilson R, Morice AH. Rococo study: a real-world evaluation of an over-the-counter medicine in acute cough (a multicentre, randomised, controlled study). *BMJ Open*. 2017;7(1):e014112. doi:10.1136/bmjopen-2016-014112
- Nicolucci A, Rossi MC, Petrelli M. Effectiveness of *Ascophyllum nodosum* and *Fucus vesiculosus* on metabolic syndrome components: a real-world, observational study. *J Diabetes Res*. 2021;2021:3389316. doi:10.1155/2021/3389316
- Vollert J, Kleykamp BA, Farrar JT, et al. Real-world data and evidence in pain research: a qualitative systematic review of methods in current practice. *Pain Rep*. 2023;8(2):e1057. doi:10.1097/PR9.0000000000001057
- Baumfeld Andre E, Reynolds R, Caubel P, Azoulay L, Dreyer NA. Trial designs using real-world data: the changing landscape of the regulatory approval process. *Pharmacoepidemiol Drug Saf*. 2020;29(10):1201–1212. doi:10.1002/pds.4932
- Kartha SS, Kulyadi GP, Bhat K, Sathyanarayana MB. Switching drugs from Rx to OTC status – a regulatory perspective. *J Young Pharm*. 2017;9(1):3–7.
- Fendrick AM, Shaw M, Schachtel B, et al. Self-selection and use patterns of over-the-counter omeprazole for frequent heartburn. *Clin Gastroenterol Hepatol*. 2004;2(1):17–21. doi:10.1016/S1542-3565(03)00287-8
- Paluch E, Jayawardena S, Wilson B, Farnsworth S. Consumer self-selection, safety, and compliance with a novel over-the-counter ibuprofen 600-mg immediate-release and extended-release tablet. *J Am Pharm Assoc*. 2016;56(4):397–404. doi:10.1016/j.japh.2016.03.003
- Guillard H, Laurora I, Sober S, Karapet A, Brass EP, Glasier A. Modeling the potential benefit of an over-the-counter progestin-only pill in preventing unintended pregnancies in the U.S. *Contraception*. 2023;117:7–12. doi:10.1016/j.contraception.2022.10.006
- Wang X, Cheng Z. Cross-sectional studies: strengths, weaknesses, and recommendations. *Chest*. 2020;158(1s):S65–s71. doi:10.1016/j.chest.2020.03.012
- Storr M, Weigmann H, Landes S, Michel MC. Self-medication for the treatment of abdominal cramps and pain-a real-life comparison of three frequently used preparations. *J Clin Med*. 2022;11(21):6361. doi:10.3390/jcm11216361
- Bédard A, Basagaña X, Anto JM, et al. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: the MASK study. *J Allergy Clin Immunol*. 2019;144(1):135–143.e136. doi:10.1016/j.jaci.2019.01.053
- Azzi EA, Kritikos V, Peters MJ, et al. Understanding reliever overuse in patients purchasing over-the-counter short-acting beta(2) agonists: an Australian community pharmacy-based survey. *BMJ Open*. 2019;9(8):e028995. doi:10.1136/bmjopen-2019-028995
- Swanepoel W, Oosthuizen I, Graham MA, Manchaiah V. Comparing hearing aid outcomes in adults using over-the-counter and hearing care professional service delivery models. *Am J Audio*. 2023;32(2):314–322. doi:10.1044/2022_AJA-22-00130
- Ah YM, Hwang S, Jun K, et al. Real-world safety evaluation of topical corticosteroid use: a community pharmacy-based, prospective, observational study. *Basic Clin Pharmacol Toxicol*. 2019;125(4):405–413. doi:10.1111/bcpt.13238

32. Libby AM, Pace W, Bryan C, et al. Comparative effectiveness research in DARTNet primary care practices: point of care data collection on hypoglycemia and over-the-counter and herbal use among patients diagnosed with diabetes. *Med Care*. 2010;48(6 Suppl):S39–44. doi:10.1097/MLR.0b013e3181ddc7b0
33. Alemanni M, de Salvo R, Moroni B, Ehret A. A real-world evidence study evaluating Geffer effervescent granules for the symptomatic relief of digestive symptoms. *SAGE Open Med*. 2022;10:20503121221088815. doi:10.1177/20503121221088815
34. Eder P, Kowalski P, Mastalerz-Migas A, Skrzydło-Radomska B, Cichy W, Proga K. Self-medication with drotaverine among patients with common abdominal symptoms and treatment efficacy from the perspectives of patients and general practitioners-an observational, retrospective, cross-sectional study using real-world data. *J Clin Med*. 2022;11(11):3156. doi:10.3390/jcm11113156
35. Goldman M, Beaumont T. A real world evaluation of a treatment for infant colic based on the experience and perceptions of 4004 parents. *Br J Nurs*. 2017;26(5 Suppl 1):S3–s10. doi:10.12968/bjon.2017.26.Sup5.S3
36. Maihöfner C, de Haas A, Sethi V, et al. Patients' experience and utilization patterns of diclofenac gel in Germany: a real-world study with a prospective longitudinal survey and a retrospective analysis of pharmacy data. *Curr Med Res Opin*. 2023;39(1):1–13. doi:10.1080/03007995.2022.2129228
37. Hasford J, Moore N, Hoye K. Safety and usage pattern of low-dose diclofenac when used as an over-the-counter medication: results of an observational cohort study in a community-based pharmacy setting. *Int J Clin Pharmacol Ther*. 2004;42(8):415–422. doi:10.5414/CP42415
38. Zhang L, De Salvo R, Ehret A, Young K, Trapp S. Vulvovaginal candidiasis: a real-world evidence study of the perceived benefits of Canesten®. *SAGE Open Medicine*. 2022;10:20503121221085437. doi:10.1177/20503121221085437
39. Giua C, Romano F, Keber E, Pellegrino P, Perez M 3rd, Uboldi MC. A prospective real-world study of bacillus clausii evaluating use, treatment habits and patient satisfaction in Italian community pharmacies: the PEGASO study. *Drugs*. 2023;11(1):137–147. doi:10.1007/s40801-023-00402-1
40. Gaul C, Förderreuther S, Lehman W, Weiser T. Correlation of effectiveness and tolerability assessments from a pharmacy-based observational study investigating the fixed-dose combination of 400 mg ibuprofen plus 100 mg caffeine for the treatment of acute headache. *Front Neurol*. 2023;14:1273846. doi:10.3389/fneur.2023.1273846
41. Klimek L, Schumacher H, Schütt T, Gräter H, Mueck T, Michel MC. Factors associated with efficacy of an ibuprofen/pseudoephedrine combination drug in pharmacy customers with common cold symptoms. *Int J Clin Pract*. 2017;71(2):e12907. doi:10.1111/ijcp.12907
42. Phillipson G, Ramsey D, Aspley S, Fietze I. Open-label real-world pharmacy purchaser study of two fixed-dose combination OTC cold treatments; wick medina, wick daymed capsules or a combination of both. *Open J Respir Dis*. 2018;8:43–62.
43. Gaul C, Gräter H, Weiser T. Results from a pharmacy-based patient survey on the use of a fixed combination analgesic containing acetylsalicylic acid, paracetamol and caffeine by self-diagnosing and self-treating patients. *SpringerPlus*. 2016;5(1):721. doi:10.1186/s40064-016-2369-0
44. Hinkel U, Schuijt C, Erckenbrecht JF. OTC laxative use of sodium picosulfate â results of a pharmacy-based patient survey (cohort study). *Int J Clin Pharmacol Ther*. 2008;46(2):89–95. doi:10.5414/CP46089
45. Schulz M, Hämmerlein A, Hinkel U, Weis G, Gillissen A. Safety and usage pattern of an over-the-counter ambroxol cough syrup: a community pharmacy-based cohort study. *Int J Clin Pharmacol Ther*. 2006;44(9):409–421. doi:10.5414/CP44409
46. Jolicœur DG, Richter KP, Ahluwalia JS, Mosier MC, Resnicow K. Smoking cessation, smoking reduction, and delayed quitting among smokers given nicotine patches and a self-help pamphlet. *Subst Abuse*. 2003;24(2):101–106. doi:10.1080/08897070309511538
47. Kotz D, Brown J, West R. 'Real-world' effectiveness of smoking cessation treatments: a population study. *Addiction*. 2014;109(3):491–499. doi:10.1111/add.12429
48. Brown J, Beard E, Kotz D, Michie S, West R. Real-world effectiveness of e-cigarettes when used to aid smoking cessation: a cross-sectional population study. *Addiction*. 2014;109(9):1531–1540. doi:10.1111/add.12623
49. Kotz D, Brown J, West R. Prospective cohort study of the effectiveness of smoking cessation treatments used in the "real world". *Mayo Clin Proc*. 2014;89(10):1360–1367. doi:10.1016/j.mayocp.2014.07.004
50. Jackson SE, Kotz D, West R, Brown J. Moderators of real-world effectiveness of smoking cessation aids: a population study. *Addiction*. 2019;114(9):1627–1638. doi:10.1111/add.14656
51. Jackson SE, Kock L, Kotz D, Brown J. Real-world effectiveness of smoking cessation aids: a population survey in England with 12-month follow-up, 2015–2020. *Addict Behav*. 2022;135:107442. doi:10.1016/j.addbeh.2022.107442
52. Jackson SE, Cox S, Shahab L, Brown J. Prevalence of use and real-world effectiveness of smoking cessation aids during the COVID-19 pandemic: a representative study of smokers in England. *Addiction*. 2022;117(9):2504–2514. doi:10.1111/add.15903
53. Borland R, Partos TR, Cummings KM. Systematic biases in cross-sectional community studies may underestimate the effectiveness of stop-smoking medications. *Nicot Tobacco Res*. 2012;14(12):1483–1487. doi:10.1093/ntr/nts002
54. Grigg J, Morris EE, Miles E. Consumer experiences of long-term oral nicotine replacement therapy and related health information-seeking: a qualitative study. *Int J Drug Policy*. 2022;110:103897. doi:10.1016/j.drugpo.2022.103897
55. Camm AJ, Fox KAA. Strengths and weaknesses of 'real-world' studies involving non-vitamin K antagonist oral anticoagulants. *Open Heart*. 2018;5(1):e000788. doi:10.1136/openhrt-2018-000788
56. Szejder H, Amand C, Stewart A, Salazar R, Scala WAR. Real world evidence of the use of metamizole (dipyrone) by the Brazilian population. A retrospective cohort with over 380,000 patients. *Einstein*. 2022;20:eAO6353. doi:10.31744/einstein_journal/2022AO6353
57. Pasta A, Formisano E, Cremonini AL, et al. Diet and nutraceutical supplementation in dyslipidemic patients: first results of an Italian single center real-world retrospective analysis. *Nutrients*. 2020;12(7):2056. doi:10.3390/nu12072056
58. Biskupiak JE, Brixner DI, Howard K, Oderda GM. Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs. *J Pain Palliat Care Pharmacother*. 2006;20(3):7–14. doi:10.1080/J354v20n03_03
59. Smith P, Price D, Harvey R, et al. Medication-related costs of rhinitis in Australia: a nostradata cross-sectional study of pharmacy purchases. *J Asthma Allergy*. 2017;10:153–161. doi:10.2147/JAA.S128431
60. Carney AS, Price DB, Smith PK, et al. Seasonal patterns of oral antihistamine and intranasal corticosteroid purchases from Australian community pharmacies: a retrospective observational study. *Pragmat Obs Res*. 2017;8:157–165. doi:10.2147/POR.S134266
61. Price DB, Smith PK, Harvey RJ, et al. Real-life treatment of rhinitis in Australia: a historical cohort study of prescription and over-the-counter therapies for patients with and without additional respiratory disease. *Pragmat Obs Res*. 2018;9:43–54. doi:10.2147/POR.S153266
62. Austin PC, Jemere N, Chiu M. Propensity score matching and complex surveys. *Stat Methods Med Res*. 2018;27(4):1240–1257. doi:10.1177/0962280216658920

63. Kusunose K, Okushi Y, Okayama Y, et al. Association between vitamin D and heart failure mortality in 10,974 hospitalized individuals. *Nutrients*. 2021;13(2):335. doi:10.3390/nu13020335
64. Jin X, Ding C, Hunter DJ, Gallego B. Effectiveness of vitamin D supplementation on knee osteoarthritis - A target trial emulation study using data from the osteoarthritis initiative cohort. *Osteoarthritis Cartilage*. 2022;30(11):1495–1505. doi:10.1016/j.joca.2022.06.005
65. Sha S, Nguyen TMN, Kuznia S, et al. Real-world evidence for the effectiveness of vitamin D supplementation in reduction of total and cause-specific mortality. *J Intern Med*. 2023;293(3):384–397. doi:10.1111/joim.13578
66. Park JM, Lee B, Kim YS, et al. Calcium supplementation, risk of cardiovascular diseases, and mortality: a real-world study of the Korean national health insurance service data. *Nutrients*. 2022;14(12):2538. doi:10.3390/nu14122538
67. Smith PH, Zhang J, Weinberger AH, Mazure CM, McKee SA. Gender differences in the real-world effectiveness of smoking cessation medications: findings from the 2010–2011 tobacco use supplement to the current population survey. *Drug Alcohol Depend*. 2017;178:485–491. doi:10.1016/j.drugalcdep.2017.05.046
68. Brown K, Scott-Hoy B, Jennings LW. Response of irritable bowel syndrome with constipation patients administered a combined quebracho/conker tree/M. balsamea Willd extract. *World J Gastrointest Pharmacol Ther*. 2016;7(3):463–468. doi:10.4292/wjgpt.v7.i3.463
69. Bousquet J, Devillier P, Arnavielhe S, et al. Treatment of allergic rhinitis using mobile technology with real-world data: the MASK observational pilot study. *Allergy*. 2018;73(9):1763–1774. doi:10.1111/all.13406
70. Kang MG, Song WJ, Choi S, et al. Google unveils a glimpse of allergic rhinitis in the real world. *Allergy*. 2015;70(1):124–128. doi:10.1111/all.12528
71. Wessel D, Pogrebnyakov N. Using social media as a source of real-world data for pharmaceutical drug development and regulatory decision making. *Drug Saf*. 2024;47:495–511.
72. Redd D, Workman TE, Shao Y, et al. Patient dietary supplements use: do results from natural language processing of clinical notes agree with survey data? *Med Sci*. 2023;11(2):37. doi:10.3390/medsci11020037
73. Flynn R, Hedenmalm K, Murray-Thomas T, et al. Ability of primary care health databases to assess medicinal products discussed by the European Union Pharmacovigilance Risk Assessment Committee. *Clin Pharmacol Ther*. 2020;107(4):957–965. doi:10.1002/cpt.1775
74. Park JS, Lee CH. Clinical study using healthcare claims database. *J Rheum Dis*. 2021;28(3):119–125. doi:10.4078/jrd.2021.28.3.119
75. Rotenstein LS, Holmgren AJ, Horn DM, et al. System-level factors and time spent on electronic health records by primary care physicians. *JAMA Netw Open*. 2023;6(11):e2344713. doi:10.1001/jamanetworkopen.2023.44713

Pragmatic and Observational Research

Publish your work in this journal

Pragmatic and Observational Research is an international, peer-reviewed, open access journal that publishes data from studies designed to reflect more closely medical interventions in real-world clinical practice compared with classical randomized controlled trials (RCTs). The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/pragmatic-and-observational-research-journal>

Dovepress
Taylor & Francis Group